Главная страница
Навигация по странице:

  • Псориаз 463

  • Болезни кожи 464

  • Псориаз 465

  • Болезни кожи 466

  • Псориаз 467

  • Болезни кожи 468

    		•

    Инфляция в РФ. По ведению больных инфекциями,передаваемыми половым путем,и урогенитальными инфекциями


    Скачать 3.48 Mb.
    НазваниеПо ведению больных инфекциями,передаваемыми половым путем,и урогенитальными инфекциями
    АнкорИнфляция в РФ
    Дата14.02.2020
    Размер3.48 Mb.
    Формат файлаpdf
    Имя файла2335_maket_30.pdf
    ТипДокументы
    #108495
    страница58 из 96
    1   ...   54   55   56   57   58   59   60   61   ...   96
    Болезни кожи
    462
    8. Kaufmann R., Bibby A., Bissonnette R. et al. A new calcipotriol/betametha- sone dipropionate formulation (daivobetTM) is an effective once-daily treat- ment for psoriasis vulgaris. dermatology 2002; 205: 389—393.
    9. Koo J., Cuffie C. A., Tanner d. J. et al. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther 1998; 20 (2):
    283—291.
    10. Lowe N., Feldman S. R., Sherer d. et al. Clobetasol propionate lotion, an ef- ficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. J dermatolog Treat 2005; 16:
    158—164.
    11. Papp K. A., Guenther L., Boyden B. et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treat- ment of psoriasis. J Am Acad dermatol 2003; 48: 48—54.
    12. Jarratt M. T., Clark S. d., Savin R. C. et al. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque type psoriasis.
    Cutis 2006; 78: 348—354.
    13. douglas W. S., Poulin Y., decroix J. et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with be- tamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta derm Ve- nereol 2002; 82: 131—135.
    14. Guenther L., van de Kerkhof P. C., Snellman E. et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of pso- riasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial.
    Br J dermatol 2002; 147:316—323.
    15. Kragballe K., Noerrelund K. L., Lui H. et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calci- potriol ointment in psoriasis vulgaris. Br J dermatol 2004; 150: 1167—1173.
    16. Ortonne P., Kaufmann R., Lecha M., Goodfield M. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. dermatology 2004; 209: 308—313.
    17. Костинский Г. Б., Кубанов А. А., Петровский Ф. И. Лечение легкого и средне-тяжелого папулезно-бляшечного псориаза активированным пиритионом цинка («Скин-кап») и качество жизни пациентов. Україн- ський журнал дерматології, венерології, косметології 2012; 46 (3): 49—52.
    18. Sadeghian G., Ziaei H., Nilforoushzadeh M. A. Treatment of localized pso- riasis with a topical formulation of zinc pyrithione. Acta dermatovenerol Alp
    Pannonica Adriat 2011; 20 (4): 187—190.

    Псориаз
    463
    19. Coven T. R., Burack L. H., Gilleaudeau R. et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe pso- riasis in patients compared with broadband UV-B. Arch dermatol 1997; 133:
    1514—1522.
    20. Snellman E., Klimenko T., Rantanen T. Randomized half-side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoria- sis. Acta derm Venereol 2004; 84: 132—137.
    21. Bagel J. LCd plus NB-UVB reduces time to improvement of psoriasis vs NB-
    UVB alone. J drugs dermatol 2009; 8 (4): 351—357.
    22. de Leeuw J., Van Lingen R. G., Both H. et al. A comparative study on the efficacy of treatment with 585 nm pulsed dye laser and ultraviolet BTL01 in plaque type psoriasis. dermatol Surg 2009; 35: 80—91.
    23. Leenutaphong V., Nimkulrat P., Sudtim S. Comparison of phototherapy two times and four times a week with low doses of narrow-band ultraviolet B in
    Asian patients with psoriasis. Photodermatol Photoimmunol Photomed 2000;
    16 (5): 202—206.
    24. Yones S. S., Palmer R. A., Garibaldinos T. T. et al. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch dermatol 2006; 142: 836—842.
    25. Goldinger S. M., dummer R., Schmid P. et al. Excimer laser versus narrow- band UVB (311 nm) in the treatment of psoriasis vulgaris. dermatology 2006;
    213 (2):134—139.
    26. Kaur M., Oliver B., H. J., Feldman S. R. Nonlaser UVB-targeted photothera- py treatment of psoriasis. Cutis 2006; 78: 200—203.
    27. Grundmann-Kollmann M., Ludwig R., Zollner T. M. et al. Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis.
    J Am Acad dermatol 2004; 50: 734—739.
    28. Олисова О. Ю., Владимиров В. В., Смирнов К. В. и др. Сравнительная эффективность узкополосной УФБ-терапии 311 нм при псориазе.
    Российский журнал кожных и венерических болезней 2011; 1: 36—40.
    29. Housman T. S., Pearce d. J., Feldman S. R. A maintenance protocol for pso- riasis plaques cleared by the 308 nm excimer laser. J dermatolog Treat 2004;
    15: 94—97.
    30. Katugampola G. A., Rees A. M., Lanigan S. W. Laser treatment of psoriasis.
    Br J dermatol. 1995; 133: 909—913.
    31. Trehan M., Taylor C. R. Medium-dose 308-nm excimer laser for the treat- ment of psoriasis. J Am Acad dermatol 2002; 47: 701—708.
    32. Feldman S. R., Mellen B. G., Housman T. S. et al. Efficacy of the 308-nm ex- cimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad dermatol 2002; 46: 900—906.

    Болезни кожи
    464
    33. Kirby B., Buckley d. A., Rogers S. Large increments in psoralen-ultraviolet
    A (PUVA) therapy are unsuitable for fair-skinned individuals with psoriasis.
    Br J dermatol. 1999; 140: 661—666.
    34. Buckley d. A., Healy E., Rogers S. A comparison of twice weekly MPd-PU-
    VA and three times-weekly skin typing-PUVA regimens for the treatment of psoriasis. Br J dermatol 1995; 133 (3): 417—422.
    35. Berg M., Ros A. M. Treatment of psoriasis with psoralens and ultraviolet A.
    A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen.
    Photodermatol Photoimmunol Photomed 1994; 10 (5): 217—220.
    36. Cooper E. J., Herd R. M., Priestley G. C., Hunter J. A. A comparison of bath water and oral delivery of 8-methoxypsoralen in PUVA therapy for plaque pso- riasis. Clin Exp dermatol 2000; 25 (2): 111—114.
    37. Amornpinyokeit N., Asawanonda P. 8-Methoxypsoralen cream plus targeted narrowband ultraviolet B for psoriasis. Photodermatol Photoimmunol Pho- tomed 2006; 22: 285—289.
    38. Asawanonda P., Amornpinyokeit N., Nimnuan C. Topical 8-methoxypso- ralen enhances the therapeutic results of targeted narrowband ultraviolet B phototherapy for plaque-type psoriasis. J Eur Acad dermatol Venereol 2008;
    22: 50—55.
    39. Schiener R., Brockow T,. Franke A. et al. Bath PUVA and saltwater baths fol- lowed by UV-B phototherapy as treatments for psoriasis: a randomized con- trolled trial. Arch dermatol 2007; 143: 586—596.
    40. Collins P., Rogers S. Bath-water compared with oral delivery of 8-methoxy- psoralen PUVA therapy for chronic plaque psoriasis. Br J dermatol 1992; 127
    (4): 392—395.
    41. Calzavara-Pinton P. G., Ortel B., Honigsmann H. et al. Safety and effective- ness of an aggressive and individualized bath-PUVA regimen in the treatment of psoriasis. dermatology 1994; 189: 256—259.
    42. Vongthongsri R., Konschitzky R., Seeber A. et al. Randomized, double-blind comparison of 1 mg/L versus 5 mg/L methoxsalen bath-PUVA therapy for chronic plaque-type psoriasis. J Am Acad dermatol 2006; 55 (4): 627—631.
    43. Волнухин В. А., Самсонов В. А., Кравцова И. В. и др. Эффективность лечения больных псориазом ПУВА-ваннами. Вестник дерматологии и венерологии 2006; 5: 56—61.
    44. Morison W. L., Baughman R. d., day R. M. et al. Consensus workshop on the toxic effects of long-term PUVA therapy. Arch dermatol 1998; 134: 595—598.
    45. Racz E., Prens E. P. Phototherapy and photochemotherapy for psoriasis. der- matol Clin 2015; 33: 79—89.
    46. Жилова М. Б., Волнухин В. А., Дворников А. С. Клинические про явления фотоповреждения кожи при многокурсовой фототерапии больных псориазом. Вестн дерматол и венерол 2014; 6: 114—120.

    Псориаз_465'>Псориаз
    465
    47. Archier E., devaux S., Castela E. et al. Carcinogenic risks of Psoralen UV-A
    Therapy and Narrowband UV-B Therapy in chronic plaque psoriasis: a system- atic literature review. J Eur Acad dermatol Venereol 2012; 26 (Suppl. 3): 22—31.
    48. Chuang T. Y., Heinrich L. A., Schultz M. d. et al. PUVA and skin cancer: a his- torical cohort study on 492 patients. J Am Acad dermatol 1992; 26: 173—177.
    49. Forman A. B., Roenigk H. H. Jr, Caro W. A., Magid M. L. Long-term follow- up of skin cancer in the PUVA-48 cooperative study. Arch dermatol 1989; 125:
    515—519.
    50. Hearn R. M., Kerr A. C., Rahim K. F. et al. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J dermatol
    2008; 159: 931—935.
    51. Lindelof B. Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis: do the known risks now outweigh the benefits? drug Saf 1999; 20: 289—297.
    52. Marcil I., Stern R. S. Squamous-cell cancer of the skin in patients given PUVA and cyclosporin: nested cohort crossover study. Lancet 2001; 358: 1042—1045.
    53. Nijsten T. E., Stern R. S. The increased risk of skin cancer is persistent after discontinuation of psoralen 1 ultraviolet A: a cohort study. J Invest dermatol
    2003; 121: 252—258.
    54. Murase J. E., Lee E. E., Koo J. Effect of ethnicity on the risk of developing nonmelanoma skin cancer following long-term PUVA therapy. Int J dermatol
    2005; 44: 1016—1021.
    55. Stern R. S., Lunder E. J. Risk of squamous cell carcinoma and methoxsalen
    (psoralen) and UV-A radiation (PUVA): a metaanalysis. Arch dermatol 1998;
    134: 1582—1585.
    56. Stern R. S., Nichols K. T., Vakeva L. H. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation
    (PUVA): the PUVA follow-up study. N Engl J Med 1997; 336: 1041—1045.
    57. Archier E., devaux S., Castela E. et al. Ocular damage in patients with pso- riasis treated by Psoralen UV-A therapy or Narrow Band UVB therapy. J Eur
    Acad dermatol Venereol 2012; 26 (Suppl. 3): 32—35.
    58. Nast A., Boehncke W.-H., Mrowietz U. et al. S3 — Guidelines on the treat- ment of psoriasis vulgaris (English version). Update. J dtsch dermatol Ges
    2012; 10 (Suppl.2): S1—95.
    59. Revicki d., Willian M. K., Saurat J. H. et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J dermatol 2008; 158: 549—557.
    60. Saurat J. H., Stingl G., dubertret L. et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J dermatol 2008; 158
    (3): 558—566.

    Болезни кожи
    466
    61. van Lingen R. G., de Jong E. M., Berends M. A. et al. Good clinical response to anti-psoriatic treatment with adalimumab and methotrexate does not inflict a direct effect on compartmentalization of T-cell subsets: a pilot study. J der- matolog Treat 2008; 19: 284—287.
    62. Flytström I., Stenberg B., Svensson A., Bergbrant I. M. Methotrexate vs. ci- closporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J dermatol 2008; 158 (1): 116—121.
    63. Heydendael V. M., Spuls P. I., Opmeer B. C. et al. Methotrexate versus cyclo- sporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;
    349 (7): 658—665.
    64. Salim A., Tan E., Ilchyshyn A., Berth-Jones J. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J dermatol 2006; 154 (6): 1169—1174.
    65. Chladek J., Simkova M., Vaneckova J. et al. The effect of folic acid supple- mentation on the pharmacokinetics and pharmacodynamics of oral metho- trexate during the remission-induction period of treatment for moderate-to- severe plaque psoriasis. Eur J Clin Pharmacol 2008; 64 (4): 347—355.
    66. Ranjan N., Sharma N. L., Shanker V. et al. Methotrexate versus hydroxy- carbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study. J dermatolog Treat 2007; 18 (5): 295—
    300.
    67. Kalb R. E., Strober B., Weinstein G., Lebwohl M. Methotrexate and psoriasis:
    2009 National Psoriasis Foundation Consensus Conference. J Am Acad der- matol 2009; 60: 824—837.
    68. Paul B. S., Momtaz K., Stern R. S. et al. Combined methotrexate—ultravio- let B therapy in the treatment of psoriasis. J Am Acad dermatol 1982; 7 (6):
    758—762.
    69. Morison W. L., Momtaz K., Parrish J. A., Fitzpatrick T. B. Combined meth- otrexate-PUVA therapy in the treatment of psoriasis. J Am Acad dermatol
    1982; 6 (1): 46—51.
    70. Asawanonda P., Nateetongrungsak Y. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad dermatol 2006; 54 (6): 1013—1018.
    71. Mahajan R., Kaur I., Kanvar A. J. Methotrexate/narrowband UVB photo- therapy combination vs. narrowband UVB phototherapy in the treatment of chronic plaque-type psoriasis—a randomized single-blinded placebo-con- trolled study. J Eur Acad dermatol Venereol 2010; 24 (5): 595—600.
    72. Kragballe K., Jansen C. T., Geiger J. M. et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta derm Venereol 1989; 69 (1): 35—40.

    Псориаз
    467
    73. Ezquerra G. M., Regana M. S., Millet P. U. Combination of acitretin and oral calcitriol for treatment of plaquetype psoriasis. Acta derm Venereol 2007;
    87: 449—450.
    74. van de Kerkhof P. C., Cambazard F., Hutchinson P. E. et al. The effect of ad- dition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in pso- riasis. Br J dermatol 1998; 138: 84—89.
    75. Caproni M., Antiga E., Melani L. et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a ran- domized-controlled trial. J Clin Immunol 2009; 29: 210—214.
    76. Gisondi P., del Giglio M., Cotena C., Girolomoni G. Combining etan- ercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigatorblinded pilot trial. Br J dermatol 2008;
    158: 1345—1349.
    77. Caca-Biljanovska N. G., V’Lckova-Laskoska M. T. Management of guttate and generalized psoriasis vulgaris: prospective randomized study. Croat Med J
    2002; 43: 707—712.
    78. Gupta A. K., Goldfarb M. T., Ellis C. N., Voorhees J. J. Side-effect profile of acitretin therapy in psoriasis. J Am Acad dermatol 1989; 20: 1088—1093.
    79. Mittal R., Malhotra S., Pandhi P. et al. Efficacy and safety of combination
    Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, doubleblind, placebo-controlled clinical trial. Arch dermatol 2009; 145: 387—393.
    80. Saurat J. H., Geiger J. M., Amblard P. et al. Randomized double-blind multi- center study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. dermatologica 1988; 177 (4): 218—224.
    81. Lauharanta J., Geiger J. M. A double-blind comparison of acitretin and etreti- nate in combination with bath PUVA in the treatment of extensive psoriasis.
    Br J dermatol 1989; 121: 107—112.
    82. Ozdemir M., Engin B., Baysal I., Mevlitoglu I. A randomized comparison of acitretin-narrow-band TL-01 phototherapy and acitretinpsoralen plus ultra- violet A for psoriasis. Acta derm Venereol 2008; 88: 589—593.
    83. Carlin C. S., Callis K. P., Krueger G. G. Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch dermatol. 2003; 139: 436—442.
    84. Ellis C. N., Fradin M. S., Messana J. M. et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991;
    324 (5): 277—284.
    85. Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br J dermatol 1998;
    139: 88—95.

    Болезни кожи
    468
    86. Thaci d., Brautigam M., Kaufmann R. et al. Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. dermatology 2002; 205 (4): 383—388.
    87. Hashizume H., Ito T., Yagi H. et al. Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris. J dermatol 2007; 34: 430—434.
    88. Yoon H. S., Youn J. I. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis. J dermatolog Treat 2007; 18 (5): 286—290.
    89. Mahrle G., Schulze H. J., Farber L. et al. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involve- ment. J Am Acad dermatol 1995; 32 (1): 78—88.
    90. Elder C. A., Moore M., Chang C. T. et al. Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. J Clin Pharma- col 1995; 35 (9): 865—875.
    91. Finzi A. F. Mozzanica N., Pigatto P. d. et al. Cyclosporine versus etretinate:
    Italian multicentre comparative trial in severe psoriasis. dermatology 1993;
    187 (Suppl 1): 8—18.
    92. Gisondi P., del Giglio M. d., Francesco V. et al. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigatorblinded clinical trial. Am J Clin Nutr 2008; 88: 1242—1247.
    93. Laburte C., Grossman R., Abi-Rached J. et al. Efficacy and safety of oral cy- closporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J dermatol 1994; 130 (3): 366—375.
    94. Levell N. J., Shuster S., Munro C. S., Friedmann P. S. Remission of ordinary psoriasis following a short clearance course of cyclosporin. Acta derm Vene- reol 1995; 75 (1): 65—69.
    95. Meffert H., Brautigam M., Farber L., Weidinger G. Low dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile. Acta derm Venereol 1997; 77 (2): 137—141.
    96. Reitamo S., Spuls P., Sassolas B. et al. Efficacy of sirolimus (rapamycin) ad- ministered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J dermatol
    2001; 145: 438—445.
    97. Agnew K. L., Bunker C. B. Multiple cutaneous squamous carcinoma in a psoriatic associated with ciclosporin, alcohol abuse and ultraviolet radiation exposure which were suppressed by acitretin. J Eur Acad dermatol Venereol
    2003; 17: 113—114.
    98. Paul C. F., Hо V. C., McGeown C. et al. Risk of malignancies in psoriasis pa- tients treated with cyclosporine: a 5 y cohort study. J Invest dermatol 2003;
    120: 211—216.

    1   ...   54   55   56   57   58   59   60   61   ...   96

    написать администратору сайта